James Noble, M.A.

James Noble, M.A., most recently served as chief executive officer of Adaptimmune Therapeutics plc until 2019 after co-founding it in 2008 and served on the board of directors until May 2023. Prior, Mr. Noble was chief executive officer of Immunocore, which he also co-founded. Mr. Noble has also served as a non-executive board director for publicly traded life science companies, including as deputy chairman of GW Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in 2021. Currently, Mr. Noble is chairman of Orexo AB, Sutura Therapeutics and IngenOx Therapeutics (formerly Celleron Therapeutics). Mr. Noble received an M.A. from the University of Oxford.